GlassScriptPhysician profile
Rachel Ann Jamison
NPI 1861122483
$1,727.98
in general payments reported to CMS, 2019-2025
34 companies · $1,728 in 2025
The $1,728 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.98 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $283.84 | 2025 | |
| Abbvie INC. | $174.14 | 2025 | |
| Merck Sharp & Dohme LLC | $106.65 | 2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $98.86 | 2025 | |
| Seagen INC. | $95.00 | 2025 | |
| Lilly USA, LLC | $70.46 | 2025 | Verzenio, Jaypirca |
| Pfizer INC. | $67.93 | 2025 | |
| Astellas Pharma US INC | $62.09 | 2025 | Xtandi |
| Springworks Therapeutics, INC. | $56.55 | 2025 | Ogsiveo |
| E.R. Squibb & Sons, L.L.C. | $55.90 | 2025 | Opdivo |
| Janssen Biotech, INC. | $53.77 | 2025 | Rybrevant, Erleada |
| Glaxosmithkline, LLC. | $53.74 | 2025 | Ojjaara, Blenrep |
| Sobi, INC | $46.98 | 2025 | |
| Geron Corporation | $45.09 | 2025 | Rytelo |
| Exelixis INC. | $42.43 | 2025 | Cabometyx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $39.20 | 2025 | Polivy, Itovebi |
| Astrazeneca Pharmaceuticals LP | $39.10 | 2025 | Lynparza, Enhertu |
| Aveo Pharmaceuticals, INC. | $38.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.24 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.60 | 2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $22.02 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $21.56 | 2025 | |
| Caris Mpi, INC. | $20.06 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $19.54 | 2025 | |
| Kyowa Kirin, INC. | $19.15 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $19.08 | 2025 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $19.00 | 2025 | Iclusig |
| Celgene Corporation | $18.15 | 2025 | Reblozyl |
| Apellis Pharmaceuticals, INC. | $17.96 | 2025 | Empaveli |
| Genmab U.S., INC. | $17.87 | 2025 | Epkinly |
| Tersera Therapeutics LLC | $15.29 | 2025 | Xermelo |
| Coherus Oncology, INC. | $14.80 | 2025 | Udenyca |
| Legend Biotech USA INC. | $13.99 | 2025 | Carvykti |
| Iovance Biotherapeutics, INC. | $7.59 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Jamison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.